Crystal structure of the A domain from the a subunit of integrin CR3 (CD11 b/CD18)  by Lee, Jie-Oh et al.
Cell, Vol. 80, 631-638, February 24, 1995, Copyright © 1995 by Cell Press 
Crystal Structure of the A Domain 
from the a Subunit of Integrin CR3 (CD11b/CD18) 
Jie-Oh Lee,* Philippe Rieu,t M. Amin Arnaout,t 
and Robert Liddington* 
* Laboratory of X-Ray Crystallography 
Dana Farber Cancer Institute 
and Department of Biological Chemistry 
and Molecular Pharmacology 
Harvard Medical School 
Boston, Massachusetts 02115 
1Leukocyte Biology and Inflammation Program 
Nephrology Division 
Department of Medicine 
Massachusetts General Hospital 
and Harvard Medical School 
Charlestown, Massachusetts 02129 
Summary 
We have determined the high resolution crystal struc- 
ture of the A domain from the (~ chain of integrin CR3. 
The domain adopts a classic a/I] "Rossmann" fold and 
contains an unusual Mg =+ coordination site at its sur- 
face. One of the coordinating ligands is the glutamate 
side chain from another A domain molecule. We sug- 
gest that this site represents a general metal ion-depen- 
dent adhesion site (MIDAS) for binding protein ligands. 
We further propose that the J~ subunits of integrins 
contain a MIDAS motif within a modified A domain. 
Our crystal structure will allow reliable models to be 
built for other members of the A domain superfamily 
and should facilitate development of novel adhesion 
modulatory drugs. 
Introduction 
The A domain is a region of approximately 200 amino acids 
that is present in one or more copies in many proteins 
involved in cell-cell, cell-matrix, and matrix-matrix nter- 
actions (Figure 1). Many members of this superfamily me- 
diate, through their A domain(s), adhesion functions that 
underlie such important physiologic processes as morpho- 
genesis, cell migration, hemostasis, inflammation, immu- 
nity, and wound healing. The genomic organization, func- 
tional diversity, and ancient lineage of the A domain 
suggest that it originated from a primordial gene that sub- 
served a morphoregulatory role, still retained in some ma- 
trix proteins, and was later incorporated into other proteins 
and modified to mediate specific adhesion events critical 
for host survival (Colombatti et al., 1993). 
The leukocyte integrin complement receptor type 3 
(CR3, also known as CD11b/CD18, ~MI32, Mol, OKM-1, 
and Mac-l) is the major integrin of phagocytic cells. It is 
a member of the 132 integrin family, which consists of four 
glycoprotein heterodimers, each with a distinct a subunit 
(CD11 a, CD11 b, CD11 c, and CD1 ld) noncovalently asso- 
ciated with a common 13 subunit (CD18) (Arnaout, 1990b; 
Cobbold et al., 1994; Rieu and Arnaout, 1995). J32 integrins 
mediate the stable adhesion of leukocytes to endothelium 
and the subsequent transendothelial migration into in- 
flamed organs (Arnaout, 1993; Hynes, 1992). CR3 also 
mediates aggregation of phagocytes (Arnaout et al., 
1985), ingestion of opsonized particles, and the generation 
of oxygen free radicals and release of hydrolytic enzymes 
=n response to particulate stimuli (Arnaout et al., 1983). 
Inherited deficiency of 132 integrins (called leukocyte adhe- 
s=on molecule deficiency or LAD) results in life-threatening 
pyogenic infections and poor wound healing due to the 
inability of circulating phagocytes to extravasate into in- 
fected tissues and to clear pathogens through phagocyto- 
sis and cell-mediated killing (Arnaout, 1990a). While es- 
sential for host survival, 132 integrin-mediated influx and 
inflammatory functions in phagocytes often exacerbate 
the local pathologic lesions and tissue injury in many non- 
infectious disease states including hemorrhagic shock, 
burns, atherosclerosis, and hyperacute rejection (Albelda 
et al., 1994; Arnaout, 1990b; Ross, 1993). In several ani- 
mal models of inflammation (Carlos and Harlan, 1990), 
monoclonal antibodies to CR3 and other 132 integrins mark- 
edly reduce the influx and inflammatory functions of leuko- 
cytes, thus preserving tissue integrity and host survival. 
Antagonists that target CR3 and other [32 integrins may 
thus be useful in therapeutic interventions of inflammatory 
diseases. 
The functions of CR3 in leukocyte extravasation and 
inflammation are mediated through its binding to several 
physiologic ligands, including iC3b, the major complement 
C3 opsonin (Arnaout et al., 1983; Wright et al., 1983), 
CD54 (intercellular adhesion molecule-I, ICAM-1 [Dia- 
mond et al., 1991 ; Simmons et al., 1988]), and the coagula- 
tion factors fibrinogen and factor X (Altieri et al., 1988). 
Recent studies have shown that the CR3 A domain (also 
called I domain) is an independent structural and func- 
tional unit, having many of the binding functions of the 
intact receptor: a recombinant CR3 A domain binds diva- 
lent cations (Michishita et al., 1993), iC3b (Ueda et al., 
1994), CD54, fibrinogen (Zhou et al., 1994), and is the 
binding site for NIF, a hookworm-derived neutrophil adhe- 
sion inhibitor (Moyle et al., 1994; Rieu et al., 1994). We there- 
fore undertook a crystallographic analysis of the CR3 A 
domain in an attempt o understand the molecular basis 
for its specific adhesive interactions and to gain insight into 
interactions mediated by other members of the A domain 
superfamily. 
Results and Discussion 
Crystal Structure of the OR3 A Domain 
We crystallized a recombinant A domain from the CD1 lb 
subunit of CR3 in the presence of Mg 2+ and solved its 
structure at 1.7 ,~, resolution using the technique of multi- 
wavelength anomalous dispersion (MAD) with a seleno- 
methionine derivative and synchrotron radiation. The elec- 
tron density map calculated from the experimental data 
was immediately interpretable (Figure 2), and a complete 
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Figure 1. Schematic of Known MembersoftheADomainSuperfamily 
(A) The plasma proteins von Willebrand factor (vWF) (Verweij et al., 
1986), complement proteins Factor B (Campbell and Porter, 1983) and 
C2 (Bentley, 1986), inter-co-trypsin inhibitor (laTI)complex subunits H2 
and H3 (Gebhard et al., 1989). 
(B) The plasma membrane proteins, a25 subunit of L-type voltage- 
dependent, dihdropyridine-sensitive (Vd-DHP-s) calcium (Ca) channel 
(Ellis et al., 1988), the ct subunits of seven integrins (CD1 la-CD1 ld, 
CD49a, CD49b, and aE) (Ignatius et al., 1990; Takada and Hemler, 
1989; Arnaout et al., 1988; Corbi et al., 1987; Larson et al., 1989; 
Shaw et al., 1994; M. Gallatin, personal communication), the protozoan 
parasite-derived proteins Plasmodium Falciparum alarial thrombos- 
pondin (rsP)-related anonymous protein (TRAP) (Robson et al., 1988), 
and Eimeria tenella microneme protein Etpl00 (Tomley et al., 1991), 
and the C. elegans-derived hypothetical protein (337.6 kDa), with a 
putative membrane-spanning region (GenBank accession number 
p34576, M. Berks and A. Smith). 
(C) The extracellular matrix proteins cartilage matrix protein (CMP) 
(Argraves et al., 1987a), collagens (Col.) VI, VII, XlI, and XIV (Chu et 
al., 1989, 1990; Gammon et al., 1992; Just et al., 1991; Yamagata et 
al., 1991); collagen VII contains a second A domain in which only the 
C-terminal half has been cloned (indicated by the closed portion of 
the domain). Key to the modular domains is shown in the box (FNIII, 
fibronectin type III motif; SCR, complement consensus repeat; TM, 
transmembrane r gion). 
model was built starting at residue D132 and finishing at 
residue K315 (numbered as in Arnaout et al., 1988) (Figure 
3). The A domain comprises alternating amphipathic c~ 
helices and hydrophobic [3 strands that conform to the 
classic a/l~ open sheet (also called "Rossmann," dinucleo- 
tide-binding, or "doubly wound") fold. Five parallel and one 
short antiparaliel 15 strands form a central sheet that is 
surrounded by seven ct helices. The primary sequence 
with secondary structure assignments is shown in Figure 
4A. A secondary structure prediction, based on an align- 
ment of known A domain sequences and FT-IR spectros- 
copy, shows remarkably good agreement with our crystal 
structure (Perkins et al., 1994). The CR3 A domain con- 
tains a single cysteine at the beginning of the domain, 
which is disordered in our crystal structure. VLA-1 (CD49a/ 
CD29, a1~1) and VLA-2 (CD49b/CD29, ~t2131) contain a 
second cysteine within the ct/~ fold: modeling studies indi- 
cate that it is buried in the interior of the domain and cannot 
participate in disulfide bond formation (data not shown). 
Certain other A domain proteins, including von Willebrand 
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Figure 2. A Portion of the Electron Density Map Superimposed on the 
Final Refined Coordinates 
(a) In!tial map calculated irectly from the experimental measurements 
at 2 A resolution. (b) Final 2Fo-Fc map calculated from experimental 
data and calculated phases at 1.7/~ resolution. 
factor (vWF) and collagens, have a cysteine at both the 
N- and C-termini of the domain that form a disulfide bridge; 
this is entirely consistent with our three-dimensional struc- 
ture, since the termini are close together in space. 
A single metal-binding site is located on the surface of 
the A domain, at the top of the 13 sheet (Figures 3 and 5). We 
ascribe the electron density peak to a Mg 2+ ion, because it 
is the only metal present in the crystallization buffer and 
the short bond distances (2.0 _+ 0.1 ,A) and octahedral 
coordination distinguish it from water. The Mg 2+ ion has 
coordination sites for six ligands: three ligands are the 
hydroxyl oxygen atoms of $142, $144, and T209, and two 
are water molecules ((01 and 0)2). 0)2 also makes a hydro- 
gen bond to the main chain carbonyl oxygen of E244. The 
two aspartates, D140 and D242, which have previously 
been implicated in metal binding (Michishita et al., 1993), 
do not coordinate the metal directly, but occupy a second- 
ary coordination sphere: each carboxylate group makes 
hydrogen bonds to water molecule (ol and one hydroxyl 
side chain (D140 to $142 and D242 to $144) (Figure 5). 
In solution, we expect the sixth Mg 2÷ coordination site to 
be occupied by a water molecule, but in our crystal struc- 
ture, it is occupied by a carboxylate oxygen atom from 
residue E314 of a neighboring A domain (bond distance 
2.0 ,,~). 
Compar i son  w i th  Other  P ro te ins  
The A domain adopts the classic dinucleotide-binding fold, 
a very common topology that is present in a wide variety 
of intracellular enzymes. The position of the ligand-binding 
site can be predicted in this class of structures from topol- 
ogy diagrams (reviewed by Branden and Tooze, 1991). A 
crevice is formed at the top of the 13 sheet, where the 
connecting loops from two 13 strands run in opposite direc- 
tions. This crevice forms a ligand-binding site in all known 
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Figure 3. Schematic Stereo Diagram of the A Domain Structure 
Strand and helix assignments are as in Figure 4A. The Mg ~+ ion is shown as a blue ball. 
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proteins of this class and often includes a metal ion. Most 
metal ions play a catalytic role and are frequently found in 
phosphoryl transfer enzymes. In the bacterial chemotaxis 
protein CheY, a Mg 2+ ion has also been shown to play an 
important structural role (Bellsolell et al., 1994). In the A 
domain, the Mg 2+ ion is found in an analogous location, 
suggesting that it may form part of a ligand-binding site 
(see below). 
There are now several atomic resolution descriptions of 
Mg 2+ coordination by proteins (Bellsolell et al., 1994; Pal 
et al., 1990; Shirakihara and Evans, 1988). The common 
features of Mg 2÷ coordination are six ligands arranged with 
octahedral geometry, bond distances of - 2.0 ,~., coordina- 
tion by oxygen atoms, and at least two ligands with formal 
negative charges. The A domain is highly unusual in hav- 
ing no negatively charged coordinating residue, except 
for that provided by the glutamate side chain from the next 
molecule. The most similar coordination is found in the 
GTPase p21 ras in complex with a GTP analog (Pal et 
al., 1990): a serine hydroxyl and a threonine hydroxyl are 
provided by the protein; the other coordinating ligands are 
two water molecules and two negatively charged phos- 
phate oxygens from GTP; an aspartate side chain occu- 
Figure 4. Primary Sequence of CD1 lb A Domain with the Secondary 
Structure, and Conservation of MIDAS in Other Domains 
(A) Sequence and secondary structure assignment of the CD11b A 
domain. MIDAS amino acid residues are indicated in bold letters. Num- 
bers refer to amino acids in the intact CD1 lb subunit (Arnaout et al., 
1988). 
(B) Alignment of the MIDAS motif in the A domain superfamily. The 
names of various proteins is preceded by h, r, ra, m, and ch to reflect 
human, rabbit, rat, mouse, or chicken origin, respectively. Other abbre- 
viations are described in the legend to Figure 1. Numbers indicate 
intervening amino acids separating the three components of MIDAS 
(DXSXS, T, and D, outlined) in each domain. 
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Figure 5. Stereo Diagram of the MIDAS Site 
Coordinating oxygen atoms are shown in red, and hydrogen bonds are shown by dashed red lines. E314 from another A domain molecule is 
shown in gold. The protein backbone is shown schematically as a gray ribbon. 
pies a secondary coordination sphere, hydrogen bonding 
to a water molecule and the serine hydroxyl, in a similar 
fashion to that in the A domain. These observations ug- 
gest that stable Mg 2÷ ion coordination requires a negatively 
charged group such as the carboxylate side chain of aspar- 
tic or glutamic acid. 
The "MIDAS" Touch 
Our results show that the Mg 2+ ion binds to a site on the 
surface of the CR3 A domain and is further coordinated 
by the glutamate side chain of another A domain molecule 
(Figure 5). Recombinant A domain has been shown to bind 
Mg 2÷ in solution and to bind certain protein ligands in a 
metal-dependent fashion: alanine mutagenesis of the 
Mg~÷-coordinating residues D140GS (to A140GA) and 
D242 abolished metal binding to the recombinant protein 
and its ability to bind iC3b and NIF (Michishita et al., 1993; 
Ueda et al., 1994; Rieu et al., 1994). Similar mutations in 
VLA-2 (CD49b/CD29) have been shown to reduce colla- 
gen binding (Kamata et al., 1994). We extended these 
observations to the interaction of CD54 and fibrinogen with 
the CR3 A domain. As can be seen in Figure 6, binding 
of CD54 and, to a lesser degree, fibrinogen, was metal 
dependent, as binding was reduced in the presence of 
EDTA or to the mutant D242A. 
These studies indicate that metal coordination within 
the A domain plays an important role in protein ligand 
binding. Our crystal structure, revealing a Mg2+-binding site 
with an extra "available" coordination site, suggests a di- 
rect role for this site in protein ligand binding. We call this 
the metal ion-dependent adhesion site (MIDAS) motif. The 
conserved features of this motif are a DXSXS sequence 
(residues 140-144, where X represent any amino acid), 
and a threonine (T209) and aspartate (D242) from other 
parts of the chain (Figure 4B). Although the X residues in 
the DXSXS sequence of CR3 are glycines, these are not 
essential, since the main chain has no unusual torsion 
angles. Inspection of the sequences of known A domains 
suggests that the majority possess a MIDAS motif, and 
many others appear to have a modified motif (Figure 4B). 
We note that the MIDAS motif consists of noncontiguous 
amino acids, as predicted (Michishita et al., 1993), unlike 
the EF-hand Ca2÷-binding motif. An analogous metal- 
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Figure 6. Effect of MIDAS on Ligand Binding to the CD11 b A Domain 
Histograms (mean _+ SD) from four independent experiments each 
done in triplicate, showing binding of fibrinogen and sCD54 to immobi- 
lized wild-type and D242A mutant CD1 lb A domain in the presence 
of divalent cations (Mg2÷/Ca2÷), and the effect of EDTA on binding of 
these proteins to wild-type A domain. Binding of iC3b, NIF, and the 
MAb 44 are shown for comparisons. Binding to the wild-type Adomain 
in the presence of cations was assigned a value of 100 for each ligand. 
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dependent protein-protein interaction has been seen re- 
cently in the complex between gelsolin and actin, in which 
a Ca 2÷ ion coordinates side chains from both proteins, 
providing abridge between them (McLaughlin et al., 1993). 
In principle, MIDAS can contribute to protein ligand bind- 
ing in two ways: directly through coordination of an acidic 
residue and/or indirectly through allosteric effects induced 
by Mg 2+ binding. Our crystallographic studies and recent 
mutagenesis data provide support for both of these mech- 
anisms, operating to different extents with different li- 
gands. Alanine mutagenesis of DE752 and EE758 in iC3b 
(Taniguchi-Sidle and Isenman, 1994) and E34 in CD54 
(Staunton et al., 1990) greatly reduced interaction of these 
ligands with CD11b/CD18 and CD1 la/CD18, respectively, 
suggesting that an acidic residue from these ligands may 
directly coordinate the Mg 2+ cation. Indirect effects may 
explain MIDAS-dependent binding of NIF, since this inter- 
action appears to require A domain residues (~413D loop) 
distant from the MIDAS motif (Rieu et al., 1994). Additional 
ligand binding and mutagenesis tudies will be required 
to evaluate these possibilities and extend them to other 
members of the A domain superfamily. 
A MIDAS Motif in Integrin p Subunits? 
Ligand recognition by integrins is not limited to their 
subunits. In integrins a,b~3 (CD41/CD61 )and ~v[33 (CD51/ 
CD61), whose a chains lack an A domain, the metal-depen- 
dent binding of several protein ligands also involves a de- 
fined region in their 13 subunits (D'Souza et al., 1988; Smith 
and Cheresh, 1988). We note that all integrin 13 subunits 
(Argraves et al., 1987b; Fitzgerald et al., 1987; Law et 
al., 1987; MacKrell et al., 1988; Hogervorst et al., 1990; 
Ramaswamy and Hemler, 1990; Sheppard et al., 1990; 
Erie et al., 1991; Moyle et al., 1991) contain an absolutely 
conserved DXSXS sequence (residues 119-123 in [33), 
and point mutations replacing D119, $121, and $123 with 
alanine in 133 abolish fibrinogen and RGD-peptide binding 
to m,b~3 (CD41/CD61) (without affecting heterodimer for- 
mation or cell surface expression) (Bajt and Loftus, 1994). 
Similarly, a mutation in [31 at D130 (equivalent to D119 in 
[33) abolishes ligand binding to ~5131 (Takada et al., 1992). 
Most significantly, RGD-containing peptides cross-link to 
a specific site on the [3 chain (K125 in [33) next to the 
DXSXS sequence. 
To explain these data, it was proposed that integrin 
subunits contain an EF-hand metal-binding motif that in- 
cludes the DXSXS sequence (Loftus et al., 1990). How- 
ever, while mutations of the DXSXS sequence abolish li- 
gand binding, mutations of aspartate residues immediately 
downstream, which would form part of the putative EF- 
hand, have no effect on ligand binding (Bajt and Loftus, 
1994). We suggest that these data are more consistent 
with a MIDAS motif in the 13 subunits, perhaps embedded 
in an A-like domain. No sequence homology has been 
detected between the ~ subunit A domain and the 13 sub- 
units using standard computer algorithms. However, the 
three-dimensional fold of the A domain, in common with 
other a/[3 open sheet structures, has a striking alternation 
of buried hydrophobic 13 strands and hydrophilic helices 
that surround the 13 sheet. This alternating pattern is re- 
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Figure 7. A Putative Integrin 13 Subunit A Domain 
Hydropathy plot comparing integrin ~ subunit A domains (solid line) 
with the putative A domain in the integrin 13 subunits (dashed line, 
residues 110-290 in 133), aligned to the DXDXS sequence. The residue 
numbers and secondary structure assignments for the CD1 lb A do- 
main are indicated. 
flected in hydropathy plots: for the c~ subunit A domain, 
the plot is a good predictor of secondary structure, with 
13 strands at the peaks and (x helices in the valleys (Figure 
7). For five other crystal structures in this class that we 
tested, similar results were obtained (data not shown). So 
we searched for parallels in hydropathic properties in the 
integrin 13 subunits. We averaged the hydropathic profiles 
for the six integrin A domains (those of CD11a-CD11c, 
CD49a, CD49b, and ctE) and all eight human integrin [3 
subunits and aligned the sequences to the DXSXS motif 
(Figure 7). The plot for the [3 subunits is remarkably similar, 
especially in the first half of the domain (e.g., residues 
110-210 in [33) (Figure 7). We therefore propose that the 
integrin 13 subunits contain a MIDAS motif within a three- 
dimensional fold similar to the (~ subunit A domain. Inter- 
estingly, this putative 13 A domain is also the site of several 
naturally occurring mutations that impair heterodimer for- 
mation in 132 integrins (reviewed by Arnaout and Michis- 
hita, 1993), suggesting a broader function of the A domain 
not only in ligand recognition but also in formation of the 
integrin heterodimeric structure. 
Concluding Remarks 
The present work elucidates the structure of an integrin 
domain and suggests a general mechanism for metal- 
mediated protein-protein i teractions. The structure should 
be valuable in elucidating the adhesion functions of the 
A domain in other members of the superfamily and may 
lead to the design of novel therapeutics. 
Experimental Procedures 
Purification and Crystallization 
Wild-type A domain was expressed as a glutathione S-transferase 
fusion protein in Escherichia coti, cleaved, and purified as described 
previously (Michishita et al., 1993). It was then digested overnight with 
0.5% immobilized trypsin (Pierce) at 4°C in phosphate-buffered saline 
(PBS) (pH 7.4), and the trypsin was removed by filtration. The protein 
was next loaded onto a Ni-NTA (Qiagen) column and eluted with a 
linear gradient of 0-200 mM imidazole. Fractions were pooled, dia- 
lyzed against 20 rnM Tris (pH 8.2), 10 mM EDTA buffer, and loaded 
onto a S-Sepharose cation exchange column (Pharmacia). The protein 
was eluted with a 0-500 mM NaCI gradient and further purified on a 
Superdex-75 gel filtration column (Pharmacia) equilibrated with 10 mM 
imidazole (pH 6.5), 60 mM KCI, and 10 mM EDTA. Finally, the protein 
was passed through a G-25 desalting column to remove EDTA and 
concentrated for crystallization using a centricon unit with a 10K molec- 
ular mass cutoff (Amicon). The selenomethionine (SeMet) derivative 
of the A domain was expressed in E. coli as described (Harrison et 
al., 1994) and purified exactly as for wild type. 
Cell 
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Crystals were grown using the sitting drop vapor diffusion method 
by mixing equal volumes (50 Id) of protein (12 mg/ml) and reservoir 
solution (12% polyethylene glycol [PEG] 8K, 0.1 M Tris [pH 8.5], 1 
mM MgCI2, 10 mM 13-mercaptoethanol) at room temperature. Crystals 
grow to a typical size of 0.5 mm x 0.05 mm x 0.05 mm in 2-3 weeks 
and belong to the tetragonal space group P43 with unit cell dimensions 
a = 45.7 A, c = 94.3 A. The SeMet A domain crystals grow under 
identical conditions and are isomorphous with the wild type. 
Data Collection and Structure Determination 
Crystals were transferred briefly into a solution containing 12% PEG 
8K, 0.1 M Tris (pH 8.5), 30% glycerol, and frozen in a stream of boiled- 
off nitrogen at 100 K prior to data collection. A low resolution data set 
was collected on a MarResearch Imaging plate using a Rigaku rotating 
anode source. All other data, including a high resolution native set, 
were collected on beam line X12C of the National Synchrotron Light 
Source at the Brookhaven National Laboratory using a MarResearch 
Imaging plate. The X-ray absorption edge of Se was determined by 
measuring the X-ray fluorescence spectrum from the crystal in situ; 
data were collected at three wavelengths: the inflection point (X1 = 
0.9797 ,&,), peak (~.2 = 0.9793/k), and plateau (X3 = 0.9300 A) of the 
Se absorption edge (Hendrickson et al., 1985). All data were reduced 
with DENZO and scaled with SCALEPACK (Otwinowski, 1991) to 
Rsymmetry = 3%-4% and data completeness = 99.5%. Three Se 
positions were determined by inspection of Difference Pattersone, re- 
finement with the program HEAVY (Terwilliger and Eisenberg, 1983), 
and inspection of Difference Fouriers. MAD phases were determined 
to 2.0 ,~, resolution using the program MLPHARE (Otwinowski, 1991) 
and combined with the SIR phases calculated from the Z3 and native 
data sets. The figure of merit was 0.65 overall to 2.0 ,~ resolution and 
varied between 0.91 at 5 ,~ and 0.46 at 2 ,~. The initial electron density 
map was immediately interpretable, and a complete atomic model was 
built, including most side chains, using the program FRODO (Jones, 
1985). The initial model was refined at 2.0 A to an R factor of 25% 
using PROLSQ (Konnert and Hendrickson, 1980) and XPLOR 
(Br(Jnger, 1992). This refined SeMet A domain structure was used 
as the initial model for the native structure. Two rounds of XPLOR 
refinement and manual rebuilding, and the addition of water mole- 
cules, produced a final model with an R factor of 21% at 1.7 ~, resolution 
(f > 2c 7-1.7 ,~,) with good geometry (rms deviation on bond length = 
0.017 A, bond angle = 3.0°). The final model contains all nonhydrogen 
atoms of residues D132 to K315 and 150 water molecules. The electron 
density for the first 5 and last 9 residues of the construct are not visible 
and are presumed to be disordered or cleaved by trypsin. 
Searches, Sequence Alignments, and Hydropathy Plots 
Homology searches were made using the BLAST program from Genet- 
ics Computer Group (GCG) Software package (Madison, Wl), se- 
quence alignments were done using GCG's pileup (gap weight 3.0 and 
a gap length weight of 0.1), and the secondary structure predictions of 
the A domain family (Perkins et al., 1994) hydropathy was calculated 
from Eieenberg'e consensus hydrophobicity index (Eisenberg, 1984) 
and averaged over a 6-residue window. The secondary structure pre- 
dictive value was assessed by analysis of the ~/13 structures of carboxy- 
peptidase, subtilisin, dihydropterine reductase, CheY, and flavodoxin. 
Coordinates were taken from the Brookhaven Protein Data Base. 
Functional Assays 
The recombinant (r) wild-type and m utani (D242A) forms of the CD1 lb 
A domain were adsorbed onto Immulon-2 96-well microtiters plates 
as described (Ueda et al., 1994). rN IF (a gift from Dr. M. Moyle [Corvas 
International Inc.]; Moyle et al., 1994), fibrinogen (Sigma), and a recom- 
binant soluble (s) form of human CD54 (sCD54, containing all five 
immunoglobulin domains but lacking the intramembranous and cyto- 
plasmic regions; a gift from Dr. J. Greve [Miles Research Center, West 
Haven, CT]; Greve et al., 1989) were labeled with sulfo-NHS-Biotin 
as described by the manufacturer (Pierce). 360 ~g of biotinylated 
sCD54 were deglycosylated (to enhance binding; Diamond et al., 
1991), using 2.4 U of N-Glycanase F (Boehringer) in presence of prote- 
ase inhibitors (2 p.g/ml each of leupeptine, chymostatin, antipain, pep- 
statin, and 2 mM phenylmethylsulfonylfluoride) for 18 hr at 37°C, and 
deglycosylation confirmed by electrophoresis of a sample on a poly- 
acrylamide gel (Laemmli, 1970) followed by Coomassie staining. To 
measure binding of biotinylated proteins to immobilized wild-type and 
mutant CDl lb  A domain, 100 ng/ml of biotinylated NIF, 8 I~g/ml of 
deglycoeylated biotinylated sCD54, and 125 p.g/ml of biotinylated fi- 
brinogen, in VBSG buffer (veronal-buffered saline (pH 7.4) with 0.10/o 
gelatin) containing 1 mM CaCI2 and I mM MgCI2 or 1 mM EDTA, were 
added to A domain-coated microtiter wells in triplicates and incubated 
at room temperature for 60 min. Wells were washed, incubated with 
alkaline phosphatase-coupled avidin, washed again, developed with 
substrate, and quantified colormetrically using a microplate reader. 
In parallel, binding of the murine anti-human CD11 b MAb 44 (Arnaout 
et al., 1983) to immobilized A domain was measured using alkaline 
phosphatase-coupled goat anti-mouse IgG. Binding of fluoresceinated 
sheep erythrocytes coated with iC3b (EAiC3b) to immobilized A do- 
main was performed as previously described (Ueda et al., 1994). 
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